Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$641K Buy
5,874
+224
+4% +$25.9K 0.12% 76
2025
Q4
$600K Sell
5,650
-99
-2% -$9.29K 0.12% 67
2025
Q3
$487K Sell
5,749
-329
-5% -$27.1K 0.1% 77
2025
Q2
$486K Buy
6,078
+715
+13% +$56.8K 0.11% 68
2025
Q1
$486K Buy
5,363
+297
+6% +$27.7K 0.13% 68
2024
Q4
$508K Sell
5,066
-271
-5% -$27.9K 0.14% 58
2024
Q3
$610K Buy
5,337
+703
+15% +$83.5K 0.17% 61
2024
Q2
$577K Buy
4,634
+772
+20% +$99.4K 0.18% 58
2024
Q1
$512K Buy
3,862
+1,342
+53% +$165K 0.17% 59
2023
Q4
$277K Buy
+2,520
New +$262K 0.11% 82

Other funds holding MRK

Second Line Capital's MRK Position: Q1 2026 in Review

Second Line Capital increased its Merck (MRK) stake by 4% in Q1 2026, buying an estimated $25.9K and bringing the position to 5,874 shares worth $641K. The position accounts for 0.12% of the portfolio, ranked #76.

Second Line Capital first reported a position in MRK in Q4 2023 and has held it in 10 quarters since. 3,775 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Second Line Capital held 5,874 shares of Merck worth $641K as of Q1 2026.
  • Second Line Capital bought 224 Merck shares in Q1 2026, an estimated $25.9K.
  • Merck made up 0.12% of Second Line Capital's portfolio in Q1 2026, its #76 holding.
  • Second Line Capital first reported a position in Merck in Q4 2023 and has held it in 10 quarters since.
  • 3,775 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Second Line Capital's 13F filing for Q1 2026, filed 15 May 2026.